---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061558"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:36:37.810938+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics Q3 2023 net loss $8.4M; cash runway into Q2 2024

## Summary
- Net loss of $8.4M in Q3 2023, versus $8.7M loss in Q3 2022; no revenue recognized.
- Cash and equivalents $43.0M as of Sept 30, 2023; expected to fund operations into Q2 2024.
- R&D expenses $5.8M (+7.4% YoY) driven by CAN-2409 manufacturing and regulatory work.
- G&A expenses $3.0M (-14.3% YoY) due to lower professional service and consulting costs.
- Topline overall survival data for CAN-2409 in NSCLC expected Q2 2024; prostate cancer data in Q4 2024.

## SEC filing metadata
- accession: 0000950170-23-061558
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017023061558/0000950170-23-061558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017023061558/cadl-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061558
- JSON: https://secwatch.observer/filing/0000950170-23-061558.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061558.txt

## Key facts
- Earnings Releases
  Candel Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Candel Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000095017023061558/0000950170-23-061558-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.